A generic is a copy of a simple chemical drug, while a biosimilar is a highly similar version of a complex biologic medicine, like adalimumab. "No clinically meaningful difference" means that any tiny variations found in rigorous testing don't affect a patient's safety or how well the drug works. The entry of Indian biosimilars for those medicines has been a game-changer, slashing prices and improving access dramatically.
Reading those dense equivalence studies late at night on my balcony, the transistor humming softly, I feel this mix of professional pride and personal relief. It's the science that assures me treatments for conditions like my father's arthritis could become affordable.
#athletics#track-and-field
Jump in to reply — no account needed.